Please login to the form below

Not currently logged in

Earnings increase for Takeda

Japan-based Takeda Pharmaceutical has recorded an increase in net income of 17.9 per cent in its financial report for the second quarter of 2011

Japan-based Takeda Pharmaceutical has recorded an increase in profit of 17.9 per cent in its financial report for the second quarter of 2011. 

The company made 75.58bn yen for the period compare to 64.11bn Yen the previous year. 

Operating income was also up, increasing 8.3 per cent to 116.21bn yen. Launches for the company during the quarter included hypertension treatment Edarbi (azilsartan medoxomil), with growth for multiple myeloma treatment Velcade (bortezomib) and type 2 diabetes drug Actos (pioglitazone) also contributing towards a net sales increase of 0.7 per cent. 

In its outlook for future prospects, the company said it had formulated its '2011 - 2013 Mid-Range Plan'. 

The plan states that Takeda will invest greatly in research and development that is focused on its core therapeutic areas of metabolic conditions, oncology and the central nervous system. The company will also make significant investments in emerging markets.

Recent developments include the company's acquisition of Nycomed, which is pending review and expected to be completed by the end of September 2011.

In its review, Takeda said the Nycomed purchase would bring an “immediate and stable increase in cash flow,” as well as offering greater leverage for research and development. 

29th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...